(Q38057421)

27 August 2017

title

Hypertension management: rationale for triple therapy based on mechanisms of action (English)

1 reference

27 August 2017

Joel M Neutel

1

1 reference

27 August 2017

David H G Smith

series ordinal

2

1 reference

27 August 2017

publication date

1 October 2013

1 reference

Cardiovascular Therapeutics

27 August 2017

published in

1 reference

27 August 2017

volume

31

1 reference

27 August 2017

issue

5

1 reference

27 August 2017

page(s)

251-258

1 reference

Executive Summary: Heart Disease and Stroke Statistics--2012 Update: A Report From the American Heart Association

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Rationale for triple-combination therapy for management of high blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Triple fixed-dose combination therapy: back to the past.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Pathogenesis of essential hypertension: historical paradigms and modern insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

A unifying pathway for essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Pathophysiological mechanisms of salt-dependent hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Vascular effects of antihypertensive drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

The sympathetic system and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Renin-angiotensin-aldosterone blockade for cardiovascular disease prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Angiotensin II type 1 receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Rationale for combination therapy in hypertension management: focus on angiotensin receptor blockers and thiazide diuretics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

New class of agents for treatment of hypertension: focus on direct renin inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Identification of angiotensin II receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Differences in cardiovascular profile among calcium antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

How do thiazide and thiazide-like diuretics lower blood pressure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Current concepts of pharmacotherapy in hypertension: thiazide-type diuretics: ongoing considerations on mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Adherence to treatment guidelines and therapeutic regimens: a US claims-based benchmark of a commercial population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Identifying gaps between guidelines and clinical practice in the evaluation and treatment of patients with hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Low medication adherence and the incidence of stroke symptoms among individuals with hypertension: the REGARDS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Fixed-dose combinations improve medication compliance: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Is blood pressure control to less than 140/less than 90 mmHg in 50% of all hypertensive patients as good as we can do in the USA: or is this as good as it gets?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

When more is not better: treatment intensification among hypertensive patients with poor medication adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Physician attitudes to blood pressure control: findings from the Supporting Hypertension Awareness and Research Europe-wide survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Overcoming clinical inertia to achieve blood pressure goals: the role of fixed-dose combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Pathogenesis and Clinical Physiology of Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

Vascular effects of calcium channel antagonists: new evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12015

21 January 2018

Identifiers

DOI

10.1111/1755-5922.12015

1 reference

27 August 2017

1 reference